Abstract
Objective: To evaluate the effects of omega-3 fatty acids during pregnancy on the incidence of wheeze and asthma of children.
Methods: A search was conducted in PubMed, Embase and CENTRAL until September 2017. Randomized controlled trials (RCTs) assessing the effects of omega-3 fatty acids during pregnancy on wheeze/asthma of children were included. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. Outcomes of relative risks were pooled. Subgroup analyses were conducted.
Results: Seven RCTs involving 2047 children were included. The pooled data revealed the supplementation during pregnancy reduced the incidence of wheeze/asthma (risk ratio (RR) 0.81; 95% CI 0.66–0.99; p .04), but the incidence of childhood asthma was not significantly reduced (RR 0.89; 95% CI 0.67–1.17; p .40). Subgroup analyses indicated that the risk of childhood wheeze/asthma was significantly decreased (1) in studies located in Europe (RR 0.67 95% CI 0.51– 0.88), (2) in children whose first-degree relatives were diagnosed with allergic disease (RR 0.65 95% CI 0.49–0.85), (3) when a dose of omega −3 fatty acids ≥2000 mg/d was applied (RR 0.61 95% CI 0.45–0.81), (4) in wheeze/asthma without sensitivity (RR 0.71 95% CI 0.54–0.94).
Conclusion: The available low-quality evidence indicated that omega-3 fatty acids supplementation during pregnancy may reduce the incidence of wheeze/asthma of children, but incidence of asthma was not reduced after omega-3 fatty acids supplementation during pregnancy. More well-designed RCTs with large sample sizes need to be conducted to better understand the effectiveness of omega-3 fatty acids supplementation during pregnancy with asthma in childhood.
Disclosure statement
No potential conflict of interest was reported by the authors.